Aug
11
Sun
2013
Inauguration @ Acharya Hall
Aug 11 @ 10:00 am – 11:30 am
Disruptive Innovation: When the past doesnot predict the future? DELSA India Workshop on Big Data and Collective Innovation @ Acharya Hall
Aug 11 @ 4:30 pm – 6:15 pm

Vural Özdemir Ph.D.

Sanjeeva Srivastava Ph.D.

Aug
12
Mon
2013
Invited Talk: Biology of plant infection by Magnaporthe oryzae @ Sathyam Hall
Aug 12 @ 12:10 pm – 12:30 pm

bharatBharat B. Chattoo, Ph.D.
Professor, Faculty of Science M.S.University of Baroda, India


Biology of plant infection by Magnaporthe oryzae

The rice blast disease caused by the ascomycetous  fungus  Magnaporthe oryzae is a major constraint in rice production. Rice-M.oryzae is also emerging as a good model patho-system to investigate how the fungus invades and propagates within the host. Identification and characterisation of genes critical for fungal pathogenesis provides opportunities to explore their use as possible targets for development of strategies for combating fungal infection and to better understand the complex process of host-pathogen interaction.

We have used insertional mutagenesis and RNAi based approaches to identify pathogenesis related genes in this fungus. A large number of mutants were isolated using Agrobacterium tumefaciens mediated transformation (ATMT). Characterisation of several interesting mutants is in progress. We have identified a novel gene, MGA1, required for the development of appressoria. The mutant mga1 is unable to infect and is impaired in glycogen and lipid mobilization required for appressorium development. The glycerol content in the mycelia of the mutant was significantly lower as compared to wild type and it was unable to tolerate hyperosmotic stress. A novel ABC transporter was identified in this fungus. The abc4 mutant did not form functional appressoria, was non-pathogenic and showed increased sensitivity to certain antifungal molecules implying the role of ABC4 in multidrug resistance (MDR). Another mutant MoSUMO (MGG_05737) was isolated  using a Split Marker technique; the mutant showed defects in growth, germination and infection. Immuno-fluorescence microscopy revealed that MoSumo is localized to septa in mycelia and nucleus as well as septa in spores. Two Dimensional Gel Electrophoresis showed differences in patterns of protein expression between Wild Type B157 and MoΔSumo mutant.  We also isolated and charaterised mutants in MoALR2 (MGG_08843) and MoMNR2 (MGG_09884). Our results indicate that both MoALR2 and MoMNR2 are Mg2+ transporters, and the reduction in the levels of CorA transporters caused defects in surface hydrophobicity, cell wall stress tolerance, sporulation, appressorium formation and infection are mediated through changes in the key signaling cascades in the knock-down transformants. (Work supported by the Department of Biotechnology, Government of India)

 

 

Invited Talk: Modelling the syncytial organization and neural control of smooth muscle: insights into autonomic physiology and pharmacology @ Amriteshwari Hall
Aug 12 @ 12:20 pm – 12:43 pm

RohitRohit Manchanda, Ph.D.
Professor, Biomedical Engineering Group, IIT-Bombay, India


Modelling the syncytial organization and neural control of smooth muscle: insights into autonomic physiology and pharmacology

We have been studying computationally the syncytial organization and neural control of smooth muscle in order to help explain certain puzzling findings thrown up by experimental work. This relates in particular to electrical signals generated in smooth muscles, such as synaptic potentials and spikes, and how these are explicable only if three-dimensional syncytial biophysics are taken fully into account.  In this talk, I shall provide an illustration of outcomes and insights gleaned from such an approach. I shall first describe our work on the mammalian vas deferens, in which an analysis of the effects of syncytial coupling led us to conclude that the experimental effects of a presumptive gap junction uncoupler, heptanol, on synaptic potentials were incompatible with gap junctional block and could best be explained by a heptanol-induced inhibition of neurotransmitter release, thus compelling a reinterpretation of the mechanism of action of this agent.  I shall outline the various lines of evidence, based on indices of syncytial function, that we adduced in order to reach this conclusion. We have now moved on to our current focus on urinary bladder biophysics, where the questions we aim to address are to do with mechanisms of spike generation. Smooth muscle cells in the bladder exhibit spontaneous spiking and spikes occur in a variety of distinct shapes, making their generation problematic to explain. We believe that the variety in shapes may owe less to intrinsic differences in spike mechanism (i.e., in the complement of ion channels participating in spike production) and more to features imposed by syncytial biophysics. We focus especially on the modulation of spike shape in a 3-D coupled network by such factors as innervation pattern, propagation in a syncytium, electrically finite bundles within and between which the spikes spread, and some degree of pacemaker activity by a sub-population of the cells. I shall report two streams of work that we have done, and the tentative conclusions these have enabled us to reach: (a) using the NEURON environment, to construct the smooth muscle syncytium and endow it with synaptic drive, and (b) using signal-processing approaches, towards sorting and classifying the experimentally recorded spikes.

Rohit (1) Rohit (2)

Aug
13
Tue
2013
Delegate Talk: A Novel Versatile Human Cell Based In Vitro High Throughput Genotoxicity Screen @ Acharya Hall
Aug 13 @ 6:50 pm – 7:00 pm
Delegate Talk: A Novel Versatile Human Cell Based In Vitro High Throughput Genotoxicity Screen @ Acharya Hall | Vallikavu | Kerala | India

Sunilkumar Sukumaran, Ayyappan Nair, Madhuri Subbiah, Gunja Gupta, Lakshmi Rajakrishna, Pradeep Savanoor Raghavendra, Subbulakshmi Karthikeyan, Salini Krishnan Unni and Ganesh Sambasivam


Genotoxicity is defined as DNA damage that leads to gene mutations which can become tumorigenic. Genotoxicity testing is important to ensure drug safety and is mandatory prior to Phase I/II clinical trials of new drugs. The results from genetic toxicology studies help to identify hazardous drugs and environmental genotoxins. Currently, among others there are four tests recommended by regulatory authorities (Ames test-bacterial, chromosome aberrations; in vitro gene mutation-eukaryotic cells and in vivo test). These assays are laborious, time consuming, require large quantities of test compounds and limited by throughput challenges. The site and mechanism of genotoxicity are not revealed by these assays and data obtained from bacterial tests might not translate the same in mammals. To address these we have developed a novel, versatile, human cell based, high throughput, reporter based genotoxicity screen (Anthem’s Genotox screen). This screen is performed on genetically engineered human cell lines that express 3 reporter genes under transcriptional control of ‘early DNA damage sensors’ (p53, p21 and GADD153). These genes are involved in DNA repair, cell cycle arrest and/or apoptosis. p21 and GADD are also known to be induced in a p53 independent manner. p53 blocks G1/S transition of cell cycle while the p53 independent DNA damage block G2/M transition. Identification of the mechanism of genotoxicity helps in rational drug designing. Additionally, the platform can be used to screen other potential genotoxins from cosmetics, food and environment. Initial validation studies of the Genotox screen was performed with over 60 compounds chosen from a variety of chemical classes. The genotoxic potential of metabolites was tested using rat liver S9 fractions. The results demonstrated a sensitivity of 86.7–92.3% and a specificity of 70–78.6% when compared with currently available in vitro genotoxicity assays. This Genotox screen would prove to be an invaluable human cell based tool to weed out potential genotoxins in various industries.

Aug
14
Wed
2013
Plenary Address: Crowd-Funded Micro-Grants to Link Biotechnology and “Big Data” R&D to Life Sciences Innovation in India @ Acharya Hall
Aug 14 @ 9:20 am – 10:05 am

VuralVural Özdemir, MD, Ph.D., DABCP
Co-Founder, DELSA Global, Seattle, WA, USA


Crowd-Funded Micro-Grants to Link Biotechnology and “Big Data” R&D to Life Sciences Innovation in India

Vural Özdemir, MD, PhD, DABCP1,2*

  1. Data-Enabled Life Sciences Alliance International (DELSA Global), Seattle, WA 98101, USA;
  2. Faculty of Management and Medicine, McGill University, Canada;

ABSTRACT

Aims: This presentation proposes two innovative funding solutions for linking biotechnology and “Big Data” R&D in India with artisan small scale discovery science, and ultimately, with knowledge-based innovation:

  • crowd-funded micro-grants, and
  • citizen philanthropy

These two concepts are new, and inter-related, and can be game changing to achieve the vision of biotechnology innovation in India, and help bridge local innovation with global science.

Background and Context: Biomedical science in the 21(st) century is embedded in, and draws from, a digital commons and “Big Data” created by high-throughput Omics technologies such as genomics. Classic Edisonian metaphors of science and scientists (i.e., “the lone genius” or other narrow definitions of expertise) are ill equipped to harness the vast promises of the 21(st) century digital commons. Moreover, in medicine and life sciences, experts often under-appreciate the important contributions made by citizen scholars and lead users of innovations to design innovative products and co-create new knowledge. We believe there are a large number of users waiting to be mobilized so as to engage with Big Data as citizen scientists-only if some funding were available. Yet many of these scholars may not meet the meta-criteria used to judge expertise, such as a track record in obtaining large research grants or a traditional academic curriculum vitae. This presentation will describe a novel idea and action framework: micro-grants, each worth $1000, for genomics and Big Data. Though a relatively small amount at first glance, this far exceeds the annual income of the “bottom one billion” – the 1.4 billion people living below the extreme poverty level defined by the World Bank ($1.25/day).

We will present two types of micro-grants. Type 1 micro-grants can be awarded through established funding agencies and philanthropies that create micro-granting programs to fund a broad and highly diverse array of small artisan labs and citizen scholars to connect genomics and Big Data with new models of discovery such as open user innovation. Type 2 micro-grants can be funded by existing or new science observatories and citizen think tanks through crowd-funding mechanisms described herein. Type 2 micro-grants would also facilitate global health diplomacy by co-creating crowd-funded micro-granting programs across nation-states in regions facing political and financial instability, while sharing similar disease burdens, therapeutics, and diagnostic needs. We report the creation of ten Type 2 micro-grants for citizen science and artisan labs to be administered by the nonprofit Data-Enabled Life Sciences Alliance International (DELSA Global, Seattle: http://www.delsaglobal.org). Our hope is that these micro-grants will spur novel forms of disruptive innovation and life sciences translation by artisan scientists and citizen scholars alike.

Address Correspondence to:

Vural Özdemir, MD, PhD, DABCP
Senior Scholar and Associate Professor
Faculty of Management and Medicine, McGill University
1001 Sherbrooke Street West
Montreal, Canada H3A 1G5

Email: vural.ozdemir@alumni.utoronto.ca

Vural (1) Vural (2) Vural-Ramani